Table of Contents

Rybelsus was the first oral semaglutide tablet approved for type 2 diabetes. Today, it is no longer the only oral GLP-1 option you might hear about. For instance, oral Wegovy is a higher-dose semaglutide tablet approved for chronic weight management.

Wegovy tablets were approved in December 2025 and launched in early January 2026. The OASIS 4 data showed that Wegovy tablets 25 mg produced meaningful weight loss of around 13.6% to 16.6% over 64 weeks.

On the other hand, Rybelsus 14 mg results are much more modest. People taking 14 mg only lost 4.1% of their starting body weight in a 6-month study.

Medical disclaimer: This article is for informational purposes only and does not replace medical advice from a licensed healthcare provider. Always take Rybelsus or Wegovy tablet exactly as prescribed.

Key Takeaways

  • Weight loss with Rybelsus is usually modest compared with new obesity-dose oral GLP-1 medications like Wegovy tablet and Foundayo.
  • Rybelsus should only be taken with a prescription and medical supervision. It may not be safe for everyone, especially people with certain thyroid, pancreas, kidney, gallbladder, or gastrointestinal risks.
  • With BuyCanadianInsulin, you can get Rybelsus starting at $298 per month, plus a 10% discount with code FIRST10.

Comparing Rybelsus and Wegovy Pill for weight loss

The Wegovy pill has shown bigger weight reductions in trials, up to 14% at 64 weeks with the 25 mg dose. Meanwhile, Rybelsus produced 2-5% weight loss in its trials.

Medication Doses Population Average Weight Change
Rybelsus 3-14 mg (daily) Adults with obesity or type 2 diabetes Up to 10 lbs of weight loss at 52 weeks
Wegovy pill 1.5-25 mg (daily) Adults with obesity or overweight without diabetes Up to 33 lbs of weight loss at 64 weeks

How much weight can you lose in a month on Rybelsus?

Weight loss on Rybelsus varies a lot by dose, diet, activity level, and individual response. In a 6-month study of adults with type 2 diabetes, people weighing around 194 lbs who took Rybelsus 14 mg lost 8 lbs on average. That’s roughly 1.3 lbs per month.

However, weight loss is not linear. Some people lose little or no weight in the first month while the dose is being increased. Others may lose 2-5 lbs in the first month, especially if they experience reduced appetite and make dietary changes.

When used in adults without diabetes, Rybelsus 14 mg resulted in an average weight reduction of 5.7% of body weight (about 5.9 kg or 13 lbs) after one year. Waist circumference also decreased by 5.5 cm (2.16 in), and body mass index fell by 2 kg/m².

How much weight can you lose in a month on Wegovy tablets?

In the OASIS-4 trial, adults weighing an average of 235 lbs lost about 33 lbs after taking the 25 mg Wegovy pill for 64 weeks or 14.7 months. That’s roughly 2.2-2.3 lb per month on average.

In that same study, approximately 76% of participants on the pill lost at least 5% of their starting weight, about 60% lost 10% or more, 47% lost at least 15%, and 28% lost at least 20%.

However, weight loss is not linear. The study participants also combined a reduced-calorie diet and increased physical activity along with Wegovy tablets.

Rybelsus dosage for weight loss vs Wegovy tablets

Rybelsus and Wegovy tablets both contain semaglutide, but Wegovy is specifically used for chronic weight management in eligible patients. Here’s how they differ in dosing:

Time on treatment Rybelsus Wegovy tablets
Days 1 to 30 3 mg once daily 1.5 mg once daily
Days 31 to 60 7 mg once daily 4 mg once daily
Day 61 to 90 14 mg once daily (highest dose) 9 mg once daily
Day 91 and after – 25 mg once daily (highest dose)

Oral semaglutide is absorbed poorly if it’s taken with food, coffee, juice, or other medications. Both Rybelsus and Wegovy tablets are taken with the following specific instructions:

    • Take 1 tablet once daily, first thing in the morning.
    • Take it on an empty stomach.
    • Use only plain water (up to about 4 oz / 120 mL).
    • Swallow the tablet whole. Don’t split, crush, or chew it.
    • Wait at least 30 minutes before eating food, drinking anything other than water, or taking other oral medications.

What is the #1 weight loss pill?

The Wegovy pill has shown the largest weight loss in trials so far, reaching about 14% at 64 weeks with the 25 mg dose. Foundayo (orforglipron) followed with 12.4% weight loss, while Rybelsus produced 2-5% weight loss.

Foundayo is a newer GLP-1 oral pill that contains orforglipron, used for weight management. Unlike Rybelsus and Wegovy tablets, Foundayo doesn’t require dietary restrictions when taken. It can be taken once daily at any time of the day, with or without food.

One study compared orforglipron with Rybelsus in adults with type 2 diabetes. After 52 weeks, participants taking orforglipron 36 mg lost 19.7 lbs (9.2% of body weight), while those taking Rybelsus 14 mg lost 11 lbs (5.3%).

Here’s how Foundayo and Rybelsus differ in dosing:

Time on treatment Rybelsus Foundayo tablets
Days 1 to 30 3 mg once daily 0.8 mg once daily
Days 31 to 60 7 mg once daily 2.5 mg once daily
Day 61 to 90 14 mg once daily (highest dose) 5.5 mg once daily
Day 91 and after – Dosage may be increased to the next dosage level (9 mg,14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage. The highest dose of Foundayo is 17.2 mg once daily.

Bottom line

Rybelsus can support weight loss in some people, mainly by helping reduce appetite and improve blood sugar control, but it is not approved as a weight-loss medication. For patients who are specifically seeking treatment for obesity or chronic weight management, FDA-approved options such as Wegovy tablet or Foundayo may be more appropriate.

If you are considering Rybelsus for weight loss, especially if you do not have type 2 diabetes, talk to a healthcare provider first to understand the benefits, risks, alternatives, and whether it is the right medication for your health goals. 

Frequently Asked Questions

A clinician may prescribe Rybelsus off-label for weight loss, but it should be done under medical supervision. GLP-1 medicines can cause gastrointestinal side effects and may not be appropriate for people with certain risks, such as thyroid, pancreas, kidney, or gallbladder problems.

Rybelsus may help some people lose overall body weight, but it does not specifically target belly fat. Fat loss usually occurs throughout the body, including visceral and abdominal fat for some people.

Yes, Rybelsus may reduce appetite. Semaglutide is a GLP-1 receptor agonist, a type of medication that can help people feel full sooner and may reduce food intake. This appetite effect is one reason some people lose weight while taking it.

Some people may notice appetite changes within the first few weeks, but meaningful weight changes usually take longer. Clinical weight results are often measured after several months. In one 6-month study, people taking Rybelsus 7 mg lost about 5 lbs on average, while those taking 14 mg lost about 8 lbs on average.

Rybelsus itself is not known to cause muscle loss, but any weight loss can include some loss of lean mass, especially if calorie intake drops and protein or strength training are low. Research on semaglutide and body composition shows that weight loss can include reductions in both fat mass and lean mass, though the proportion of lean mass may improve as fat mass decreases.

You do not necessarily need to avoid all sugar, but it is smart to limit added sugars and follow the eating plan recommended by your healthcare provider. Rybelsus is meant to be used with diet and exercise for type 2 diabetes, so reducing sugary drinks, desserts, and refined carbohydrates may support blood sugar control and weight management.

Articles you may also be interested in

Sources

Joszt, L., MA. (2025, December 23). FDA approves oral semaglutide as first GLP-1 pill for weight loss. AJMC – Managed Care News, Research, and Expert Insights. https://www.ajmc.com/view/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss

RYBELSUS® Results | RYBELSUS® (semaglutide) tablets. (n.d.). https://www.rybelsus.com/why-rybelsus/rybelsus-results.html

Wharton, S., Lingvay, I., Bogdanski, P., Vale, R. D. D., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 393(11), 1077–1087. https://doi.org/10.1056/nejmoa2500969

Araki E, Terauchi Y, Watada H, Deenadayalan S, Christiansen E, Horio H, Kadowaki T. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials. Diabetes Obes Metab. 2021 Dec;23(12):2785-2794. doi: 10.1111/dom.14536. Epub 2021 Sep 27. PMID: 34472698; PMCID: PMC9293331.

Krajnc, M., Kuhar, N., & Koceva, A. (2025). Oral semaglutide for the treatment of obesity: a retrospective real-world study. Frontiers in Endocrinology, 16, 1593334. https://doi.org/10.3389/fendo.2025.1593334

Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight

Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar

Wilding, J. P. H., Batterham, R. L., Calanna, S., Van Gaal, L. F., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Impact of semaglutide on body composition in adults with overweight or obesity: Exploratory analysis of the STEP 1 study. Journal of the Endocrine Society, 5(Supplement_1), A16–A17. https://doi.org/10.1210/jendso/bvab048.030